Development of GnRH antagonists for prostate cancer: New approaches to treatment

Oncologist

Volumn 5, Issue 2, 2000, Pages 162-168

  Cook, Terry ^a   Sheridan, William P ^a  

^a AMGEN INC   (United States)

Author keywords

GnRH; Lutenizing hormone; Prostate cancer

Indexed keywords

GONADORELIN ANTAGONIST; LEUPRORELIN;

DRUG EFFECT; DRUG RECEPTOR BINDING; GROWTH INHIBITION; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 0034092671     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-2-162     Document Type: Review

References (53)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995;45:8-30.
2. Garnick MB, Fair W. Combating prostate cancer. Sci Am 1998;279:74-83.
3. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990;16:39-48.
4. Boyle P. The evolution of an epidemic of unknown origin. In: Denis L, ed. Prostate Cancer 2000. New York: Springer Verlag, 1994:5-11.
5. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogens and of androgen injections on serum phosphatase in metastatic carcinoma of the prostate. Recent Results Cancer Res 1941;1:293-297.
6. Lincoln DW. Gonadotropin-releasing hormone (GnRH): basic physiology. In: DeGroot LJ et al., eds. Endrocrinology. Philadelphia, PA: W.B. Saunders, Co., 1997:142-151.
7. Issacs WB, Issacs JT. Molecular genetics of prostate cancer progression. In: Issacs WB, ed. Principles and Practices of Genito-urinary Oncology. Baltimore, MD: Johns Hopkins Oncology Center, 1997:403-408.
8. Netto GJ, Humphrey PA. Molecular biologic aspects of human prostatic carcinoma. Am J Clin Path 1994;102:S57-S64.
9. Culig Z, Hobisch A, Cronauer MV et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405.
10. Bosland MC, Dreef Van Der Meulen HC, Sukumar S et al. Multistage prostate carcinogenesis: the role of hormones. International Symposium of the Princess Takamatsu Cancer Research Fund 1991;22:109.
11. Hayward SW, Cunha GR, Dahiya R. Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann NY Acad Sci 1996;784:50-62.
12. Fertilitext. GnRH Agonists-Lupron, Naferelin, Synaril, Goserelin, Zolodex. www.fertilitext.org accessed on 15 July 1999.
13. Eisenberger MA, O'Dwyer PJ, Friedman MA. Gondadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 1986;4:414-424.
14. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990;144:1479-1470.
15. Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990;144:934-941.
16. McDermed JE, Strum SB. Prevention of biochemical and clinical flare. PCR Insights 1999;2.
17. Bruchovsky N, Goldenberg SL, Akakura K et al. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethystilbestrol. Cancer 1993;72:1685-1691.
18. Kuhn JM, Billebaud T, Navratil H et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of antiandrogen (nilutamide). N Engl J Med 1989;321:413-418.
19. Garnick MB, Gittelman M, Steidle C et al. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound prostate gland volume reduction (PGVR) and androgen suppression before brachytherapy (BT) or radiation therapy (XRT). J Urol 1998;159:220a.
20. Smith JA, Glode LM, Wetthaufer JN et al. Clinical effects of gondadotropin-releasing hormone analogue in metastatic carcinoma of the prostate. Urol 1985;25:106-114.
21. Smith JA. Long-term effects of a GnRH analogue in patients with metastatic carcinoma of the prostate. J Urol 1984;131:209a.
22. Trachtenberg J. The treatment of metastatic prostate cancer with a potent luteinizing hormone releasing hormone analogue. J Urol 1983;129:1149-1152.
23. Vance MA, Smith JA. Endocrine and clinical effects of leuprolide in prostatic cancer. Clin Pharmacol Ther 1984;36:350-354.
24. Yamanaka H, Makino T, Yajima H et al. Efficacy of D-LEU6-des Gly-NH210-LHRH ethylamide against prostatic cancer. Prostate 1985;6:27-34.
25. Bischoff W. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. J Int Med Res 1990;18:103-113.
26. Navratil H. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer. J Int Med Res 1990;18:69-73.
27. Niijima T, Aso Y, Akaza H et al. Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Hinyokika Kiyo 1990;36:1343-1360.
28. Akaza H, Aso Y, Koiso K et al. Leuprorelin acetate depot: results of a multicentre Japanese trial. J Int Med Res 1990;15:95-102.
29. O'Brien A, Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J Int Med Res 1990;18:57-68.
30. Rizzo M, Maxxei T, Mini E et al. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res 1990;18:114-125.
31. Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 1990;143:68-71.
32. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
33. Allen JM, O'Shea JP, Mashiter K et al. Advanced carcinoma of the prostate: treatment with a gonadotropin releasing hormone agonist. Br Med J 1983;286:1607-1609.
34. Kerle D, Williams G, Ware H et al. Failure of long term luteinsing hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. Br Med J 1984;289:468-469.
35. Murray RML, Pitt P, Lawson P et al. Treatment of advanced prostatic cancer with an LHRH analogue. Br J Urol 1987;59:182a.
36. Williams G, Kerle DJ, Roe SM et al. Results obtained in the treatment of prostate cancer patients with Zoladex. In: Schroder FH, Richards B, eds. EORTC Genitourinary Group Monograph 2. New York, NY; Alan Liss Inc., 1985:287-295.
37. Ahmed SR, Grant JBF, Shalet SM et al. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response. Br J Urol 1986;58:534-538.
38. Kotake T, Usami M, Sonoda T et al. LH-RH agonist Zolodex (goserelin), depot formulation in the treatment of prostatic cancer: randomised dose-finding trial in Japan. Am J Clin Oncol 1988;11:108-111.
39. Usami M, Kotake T, Matsuda M et al. Endocrine therapy for prostatic carcinoma with slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zolodex). Hinyokika Kiyo 1988;34:369-382.
40. Garnick MB, Tomera K, Campion M et al. Abarelix-depot (A-D). A sustained-release (SR) formulation of a potent GnRH pure antagonist in patients (pts) with prostate cancer (PrCA): phase II clinical results and endocrine comparison with superagonist Lupron® (L) and Zoladex* (Z). Proc Am Soc Clin Oncol 1999;18:321a.
41. Campion M, Kuca B, Garnick MB. The magnitude of Lupron® (L) or Zoladex® (Z) testosterone (T) and Leutinizing Hormone (LH) surge is dependent on formulation: comparative results of L and Z vs abarelix-Depot (A-D), a GnRH antagonist devoid of androgen surge. Proc Am Soc Clin Oncol 1999;18:320a.
42. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
43. Pilepich MV, Krall JM, al-Saraaf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-623.
44. Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. J Urol 1997;158:1623-1624.
45. Brasso K, Friis S, Juel K et al. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999;161:524-528.
46. Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. J Urol 1999;161:505-508.
47. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-1788.
48. Denis L, Dalesio O, Murphy G. Review of phase III clinical trials on combined anti-androgen therapies in patients with metastasized prostatic cancer. Prog Urol 1993;3:75-85.
49. Boccardo F, Pace M, Rubagotti A et al. Goserlin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic cancer. Eur J Cancer 1993;29A:1088-1093.
50. Tyrell CJ, Altwein JE, Klippel F et al. Multicenter randomized trail comparing Zoladex with Zolodex plus flutamide in the treatment of advanced prostate cancer. Survival update. Cancer 1993;72:3878-3879.
51. Iverson P, Rasmussen F, Klarskov P et al. Long-term results of Danish Prostatic Cancer Group trial 86: Goserlin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993;72:3851-3854.
52. Eisenberger MA, Blumenstein BA, Crawford D et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-1042.
53. Dijkman GA, Janknegt RA, De Reijke TM et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160-163.